Norwegian Capture the Fracture Initiative (NoFRACT)

March 21, 2022 updated by: Lene Bergendal Solberg, Oslo University Hospital
The main aim is to assess the effectiveness of introducing a standardized intervention program for treatment of patients with a fragility fracture as measured by changes in the fracture rates and the mortality.

Study Overview

Detailed Description

A fracture liaison service model of care is widely recommended but data on its effectiveness regarding reduced risk of recurrent fracture and fracture related mortality are scarce. The investigators therefore aim to assess the risk of subsequent fractures and mortality after a clinical fracture in patients who present to hospitals with a standardized intervention program. Seven Norwegian hospitals will be Stepped Wedge Cluster Randomized to a standardized intervention program with startup date between May 2015 and Jan 2016. The intervention will last throughout 2018 with follow-up throughout 2019. Outcomes before and after the intervention will be compared and each hospital will act as its own control. The effect of the intervention will be measured by using national patient registries on fractures and mortality.

Study Type

Interventional

Enrollment (Actual)

94260

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bergen, Norway
        • Haukeland University Hospital
      • Drammen, Norway
        • Drammen Hospital
      • Molde, Norway
        • Molde Hospital
      • Oslo, Norway
        • Oslo University Hospital
      • Sandvika, Norway
        • Bærum Hospital
      • Tromsø, Norway
        • University Hospital of North Norway
      • Trondheim, Norway
        • St. Olavs University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Low-energy fracture

Exclusion Criteria:

  • finger fracture, toe fracture, face fracture, skull fracture

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Fracture liaison service
  • Information, assessment & lifestyle advice
  • refer to DXA scan, except patients with dementia, difficulties laying on the back or short life exp.
  • Blood samples
  • Sufficient intake of Vitamin D & calcium, combined with physical activity will be recommended with lifestyle advice (smoking & alcohol intake)
  • Patients With Hip, Vertebral or two or more low-trauma fractures are recommended treated with anti-osteoporosis drug
  • Other fractures, treatment recommended if FRAX score≥20% for major fracture & T-score≤-1.5
  • Fracture patients with reduced kidney function will be treated with anti-RANKL
  • Anti-osteoporosis drug prescribed by hospital physician
  • Follow-up phone call after 3 months and visit to talk with coordinating nurse after 1 year
  • Patients with spine or femoral neck T-scores≤-3.5, >2 severe vertebral fractures & those who suffer a second fracture while using anti-osteoporosis drug, will be referred for further examination and teriparatide treatment will be considered
Other: Current treatment
Treatment as offered before intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fragility fracture
Time Frame: 4 years
Incidence of fragility fractures per 10,000 person-years (distal forearm fractures, proximal humerus fractures and hip fractures)
4 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mortality
Time Frame: 4 years
Total number of deaths during four years after enrollment
4 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2015

Primary Completion (Actual)

January 1, 2020

Study Completion (Actual)

May 1, 2020

Study Registration Dates

First Submitted

April 30, 2015

First Submitted That Met QC Criteria

August 31, 2015

First Posted (Estimate)

September 1, 2015

Study Record Updates

Last Update Posted (Actual)

March 22, 2022

Last Update Submitted That Met QC Criteria

March 21, 2022

Last Verified

March 1, 2022

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hip Fracture

Clinical Trials on Fracture Liaison Service

3
Subscribe